Alberta Investment Management Corp Acquires 40,251 Shares of Zoetis Inc. $ZTS

Alberta Investment Management Corp increased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 108.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 77,351 shares of the company’s stock after purchasing an additional 40,251 shares during the period. Alberta Investment Management Corp’s holdings in Zoetis were worth $9,732,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. Global Wealth Strategies & Associates bought a new stake in shares of Zoetis in the fourth quarter valued at approximately $25,000. Lodestone Wealth Management LLC acquired a new stake in shares of Zoetis in the fourth quarter worth $30,000. KERR FINANCIAL PLANNING Corp bought a new position in Zoetis during the third quarter worth $31,000. Holos Integrated Wealth LLC acquired a new position in Zoetis during the 4th quarter valued at $32,000. Finally, Elyxium Wealth LLC bought a new stake in Zoetis in the 4th quarter valued at $32,000. Institutional investors own 92.80% of the company’s stock.

Insiders Place Their Bets

In other Zoetis news, Director Michael B. Mccallister bought 3,000 shares of the firm’s stock in a transaction dated Monday, May 11th. The shares were bought at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the acquisition, the director owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Paul Bisaro bought 2,000 shares of the stock in a transaction dated Wednesday, May 13th. The stock was acquired at an average price of $75.88 per share, with a total value of $151,760.00. Following the completion of the purchase, the director owned 27,862 shares of the company’s stock, valued at $2,114,168.56. This represents a 7.73% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have acquired 11,650 shares of company stock valued at $886,384. 0.22% of the stock is currently owned by corporate insiders.

Key Headlines Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: The flood of class-action reminders highlights alleged investor harm and creates another headline risk for Zoetis, which can weigh on sentiment while litigation moves forward. Article Title
• Negative Sentiment: Several law firms allege securities-law violations tied to the same class period, reinforcing uncertainty around prior disclosures and potentially keeping pressure on the stock. Article Title
• Neutral Sentiment: The company’s recent earnings backdrop remains a separate concern: Zoetis previously missed both EPS and revenue estimates, which may continue to influence investor caution.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Morgan Stanley reaffirmed an “overweight” rating and set a $115.00 price objective on shares of Zoetis in a research report on Friday, May 15th. Stifel Nicolaus lowered their price target on Zoetis from $105.00 to $95.00 and set a “hold” rating on the stock in a research note on Friday, May 22nd. Weiss Ratings cut Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday. JPMorgan Chase & Co. reduced their price objective on Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Finally, UBS Group decreased their price objective on Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a report on Friday, May 8th. Six investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $133.92.

Zoetis Price Performance

Shares of Zoetis stock opened at $79.28 on Wednesday. The stock has a market capitalization of $33.24 billion, a price-to-earnings ratio of 13.15, a P/E/G ratio of 1.25 and a beta of 0.75. The firm’s 50-day moving average price is $95.41 and its two-hundred day moving average price is $113.49. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. Zoetis Inc. has a 1-year low of $72.38 and a 1-year high of $164.32.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The firm had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business’s revenue was up 2.9% on a year-over-year basis. During the same quarter last year, the firm posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, equities analysts predict that Zoetis Inc. will post 6.88 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be given a $0.53 dividend. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a yield of 2.7%. Zoetis’s payout ratio is presently 35.16%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.